Search Results

Baxter Provides Update on COVID-19 Response Efforts

Baxter International Inc. (NYSE:BAX), a global medical products company, today provided an update on how the company is responding to the COVID-19 epidemic that is challenging communities and healthcare systems throughout the world.

Opdatering angående COVID-19

Baxter i Danmark har de seneste uger holdt flere møder med relevante myndigheder, brancheforening, m.fl. for at udveksle råd og anbefalinger i den ekstraordinære situation, som vi befinder os i. Vi gør alt der står i vores magt for at beskytte sårbare patientgrupper og de alvorligt syge COVID-19 patienter med akut behov for intensiv behandling. Her er den seneste opdatering på, hvordan Baxter bidrager med at hjælpe hospitaler, sundhedspersonale og patienter;

Baxter Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per share of common stock. The dividend is payable on April 1, 2020, to shareholders of record as of February 28, 2020. The indicated annual dividend rate is $0.88 per share of common stock. 

Baxter Completes Acquisition of Seprafilm Adhesion Barrier

Baxter International Inc. (NYSE:BAX), a leading global medical products company, has completed its previously announced acquisition of Seprafilm Adhesion Barrier and related assets from Sanofi for $350 million.

Baxter Announces Preliminary Net Sales for the Fourth-Quarter and Full-Year 2019 and Announces Preliminary Full-Year 2020 Guidance

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced preliminary net sales for the quarter and full year ended December 31, 2019, and preliminary full-year 2020 guidance for select financial metrics.

Baxter to Expand Advanced Surgery Portfolio with Acquisition of Seprafilm Adhesion Barrier

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today entered into a definitive agreement to acquire Seprafilm Adhesion Barrier and related assets from Sanofi. The agreement is the latest example of Baxter's continued focus on acquiring products and technologies that have a strong strategic fit with the company's leading portfolio across the hospital, including in the operating room.

Baxter Declares Quarterly Dividend

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today announced that its Board of Directors has declared a quarterly cash dividend of $0.22 per share of common stock. The dividend is payable on Jan. 2, 2020, to shareholders of record as of Dec. 6, 2019. The indicated annual dividend rate is $0.88 per share of common stock. About Baxter

Baxter Home Dialysis Study Associates Sharesource with 39% Reduction in Hospitalization Rates for Colombian Patients

Baxter International Inc. (NYSE:BAX), a global innovator in renal care, announced today new data associating the use of its automated peritoneal dialysis (APD) cyclers and the Sharesource remote patient management platform with a 39% reduction in hospitalizations for home PD patients receiving care at Baxter Renal Care Services clinics in Colombia.

Baxter Features Patient-Centered Innovation at the 2019 European Society of Intensive Care Medicine Congress

Baxter International Inc. (NYSE:BAX), a leading global medical products company, will showcase its latest product innovations at the 2019 European Society of Intensive Care Medicine (ESICM) LIVES congress in Berlin from Sept. 28 – Oct. 2. The company will also host symposia to advance clinical knowledge in two emerging areas: extracorporeal (outside the body) organ support and the role of personalized fluid management for patients in the intensive care unit (ICU).

Baxter Announces Acquisition of Cheetah Medical to Expand aSpecialized Patient Monitoring Portfolio

Baxter International Inc. (NYSE:BAX), a leading global medical products company, today entered into a definitive agreement to acquire Cheetah Medical, a leading provider of non-invasive hemodynamic monitoring technologies. The agreement demonstrates Baxter's ongoing commitment to improving clinical outcomes with an established patient monitoring technology to better inform and guide clinicians' treatment decisions.